This application is the national phase entry of International Application No. PCT/CN2023/076103, filed on Feb. 15, 2023, which is based upon and claims priority to Chinese Patent Application No. 202210233115.X, filed on Mar. 9, 2022, the entire contents of which are incorporated herein by reference.
The present disclosure belongs to the technical field of preparation of ophthalmic drugs, and specifically relates to an application of CB-839 in preparation of a drug for inhibiting corneal neovascularization (CNV).
The prevention and treatment of CNV is a major clinical challenge. When a cornea is affected by internal and external factors such as injury, infection, corneal operations, and genetic diseases, an excessive oxidative stress will occur in the cornea to trigger the up-regulation of pro-angiogenic factors, which causes the invasion of capillaries from a corneoscleral limbus to the cornea to produce CNV, resulting in vision loss in a patient and even blindness in severe cases.
Currently, clinical pharmaceutical and surgical prevention and treatment manners are often accompanied by complications such as glaucoma, cataract, corneal epithelial injury, or corneal superinfection. Therefore, it is urgent and necessary to develop a novel technology for preventing CNV.
In view of the above-mentioned problem that the current prevention and treatment manners for CNV may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug can significantly inhibit CNV in mice without complications, which makes up for the shortcoming of the prior art.
The present disclosure is implemented by the following technical solutions:
An application of CB-839 in preparation of a drug for inhibiting CNV is provided.
CB-839 is a non-competitive selective inhibitor for glutaminase 1 (GLS1), which exhibits a significant antiproliferative activity for cancer cell lines such as triple-negative breast cancer (TNBC), lung adenocarcinoma, chondrosarcoma, and lymphoma cell lines.
Further, the CNV is produced due to invasion of capillaries from a corneoscleral limbus to a cornea when an excessive oxidative stress occurs in the cornea to trigger up-regulation of pro-angiogenic factors.
Further, a dosage form of the drug for inhibiting CNV is a sustained-release hydrogel, a liposome, or a polylactic acid-hydroxyacetic acid copolymer microsphere.
Further, the sustained-release hydrogel refers to a hydrogel-based sustained-release agent, and a preparation method of the hydrogel-based sustained-release agent includes the following steps: thoroughly mixing gelatin with the CB-839 to obtain an aqueous solution, adding carboxymethyl cellulose (CMC) and an N-hydroxysulfosuccinimide sodium salt to the aqueous solution, thoroughly mixing a resulting mixture, and allowing the mixture to stand at room temperature to obtain the hydrogel-based sustained-release agent loaded with the CB-839.
Further, in the aqueous solution prepared by thoroughly mixing the gelatin with the CB-839, a concentration of the gelatin is 0.03 mg/mL to 0.08 mg/mL and a concentration of the CB-839 is 0.3 mg/mL to 0.5 mg/mL.
Further, in the aqueous solution prepared by thoroughly mixing the gelatin with the CB-839, the concentration of the gelatin is 0.05 mg/mL and the concentration of the CB-839 is 0.4 mg/mL.
Further, the liposome refers to a liposome-based sustained-release agent, and a preparation method of the liposome-based sustained-release agent includes the following steps: dispersing soybean lecithin, cholesterol, and the CB-839 jointly in dichloromethane (DCM) to obtain a homogeneous solution, and subjecting the homogeneous solution to evaporation under reduced pressure to dryness; dispersing a residue in water, centrifuging a resulting dispersion, and discarding a resulting supernatant; and adding water to a resulting precipitate, and thoroughly mixing a resulting mixture to obtain the liposome-based sustained-release agent loaded with the CB-839.
Further, the dispersing refers to ultrasonic dispersion.
Beneficial effects of the present disclosure: The drug obtained in the present disclosure can effectively inhibit CNV and thus can be used for a continuous treatment of CNV. The present disclosure overcomes the shortcomings of poor solubility and low bioavailability of CB-839, can reduce the inconvenience caused by multiple and frequent use of traditional preparations, and makes the drug exert an efficient and long-lasting therapeutic effect.
The present disclosure is further described in detail below with reference to specific examples.
The above examples are only intended to describe the preferred implementations of the present disclosure, rather than to limit the scope of the present disclosure. Various alterations and improvements made by those of ordinary skill in the art based on the technical solution of the present disclosure without departing from the design spirit of the present disclosure shall fall within the protection scope of the appended claims of the present disclosure.
Number | Date | Country | Kind |
---|---|---|---|
202210233115.X | Mar 2022 | CN | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/CN2023/076103 | 2/15/2023 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2023/169163 | 9/14/2023 | WO | A |
Number | Date | Country |
---|---|---|
107714650 | Feb 2018 | CN |
114917230 | Aug 2022 | CN |
WO-2019104038 | May 2019 | WO |
2022001784 | Jan 2022 | WO |
2022251370 | Dec 2022 | WO |
Entry |
---|
Hongling Huang, et al., Role of glutamine and interlinked asparagine metabolism in vessel formation, The Embo Journal, 2017, pp. 2334-2352, vol. 36 No. 16. |
Number | Date | Country | |
---|---|---|---|
20240261281 A1 | Aug 2024 | US |